Palvella Therapeutics (NASDAQ:PVLA) Trading Down 5.9% – Time to Sell?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price fell 5.9% on Tuesday . The company traded as low as $101.76 and last traded at $102.64. 72,891 shares were traded during mid-day trading, a decline of 47% from the average session volume of 138,706 shares. The stock had previously closed at $109.07.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. TD Cowen upped their price objective on Palvella Therapeutics from $97.00 to $133.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Chardan Capital increased their target price on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Stifel Nicolaus boosted their price objective on shares of Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Finally, Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of “Buy” and a consensus price target of $155.60.

Palvella Therapeutics Stock Performance

The firm’s 50-day moving average is $87.59 and its 200 day moving average is $59.10. The firm has a market capitalization of $1.25 billion, a P/E ratio of -40.24 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). As a group, research analysts expect that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total transaction of $415,013.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Clio Asset Management LLC acquired a new position in shares of Palvella Therapeutics during the 2nd quarter worth $2,063,000. Frazier Life Sciences Management L.P. lifted its stake in shares of Palvella Therapeutics by 4.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after acquiring an additional 32,388 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at $399,000. Woodline Partners LP bought a new stake in Palvella Therapeutics during the 1st quarter worth $5,435,000. Finally, Goldman Sachs Group Inc. acquired a new position in Palvella Therapeutics in the 1st quarter worth about $533,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.